Hepatitis B cirrhosis is the final result of the development of chronic hepatitis B. It is divided into compensated cirrhosis and decompensated cirrhosis. Complications such as ascites, esophagogastric fundic vein rupture and bleeding, and hepatic coma in patients with cirrhosis indicate the progression to the decompensated stage of cirrhosis. After the development of cirrhosis to the decompensated stage, the liver function will deteriorate rapidly and the mortality rate will increase significantly. For patients with compensated hepatitis B cirrhosis, the goal of treatment is to delay or reduce liver failure and reduce the incidence of hepatocellular carcinoma. Recent studies have shown that persistent hepatitis B virus replication is an important risk factor for the progression of cirrhosis, and some studies have shown that effective antiviral therapy can reduce the risk of disease progression by 55% and the risk of hepatocellular carcinoma by 51%. For patients with decompensated hepatitis B cirrhosis, antiviral therapy can delay disease progression, and although it cannot change the final outcome of patients with end-stage cirrhosis, it can improve liver function, prolong survival, and delay or reduce the need for liver transplantation. In view of the above facts, the latest liver disease guidelines both at home and abroad support that for patients with hepatitis B cirrhosis, as long as they are tested positive for HBV DNA, regardless of whether they are HBeAg positive or not, and regardless of whether their transaminase levels are elevated, they should choose effective oral antiviral drugs for antiviral treatment as soon as possible.